Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study.

ABSTRACT:

Purpose

Ramucirumab (RAM) is recommended as premedication with H₁-receptor antagonists (H₁RA) to prevent infusion-related reactions (IRRs). However, RAM is a human antibody with a low incidence of IRRs. We evaluated the noninferiority of non-H₁RA (dexamethasone [DEX] alone) premedication to H₁RA (plus DEX) premedication in terms of IRRs in patients with gastric cancer receiving RAM plus nanoparticle albumin-bound paclitaxel (nab-PTX).

Methods

This was a noninferiority, multicenter, retrospective trial conducted in three Japanese centers to assess the incidence of IRRs in patients receiving RAM plus nab-PTX for gastric cancer between 2018 and 2023. Patients with gastric cancer receiving RAM plus nab-PTX were divided into groups with

SUBMITTER: Negoro Y 

PROVIDER: S-EPMC11456548 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature